Stock Track | GeneDx Holdings Soars 5.43% on Strong Q3 Results and Raised 2025 Guidance

Stock Track10-29

GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance significantly exceeded analyst expectations, particularly in terms of revenue and adjusted earnings per share.

According to the financial report, GeneDx posted Q3 revenue of $116.7 million, substantially outperforming the IBES estimate of $104.1 million. This represents a 52% year-over-year growth. The company's adjusted earnings per share came in at $0.49, beating the consensus estimate of $0.39. Notably, exome and genome test revenue grew by 65% year-over-year, driven by a 33% increase in test volumes.

In light of the strong performance, GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, up from the previous range of $400 million to $415 million. The company also expects 53% to 55% growth in exome and genome revenue for the full year. Additionally, GeneDx announced it had received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, underscoring its innovative leadership in the genomics space. The market's enthusiastic response to these results and outlook improvements reflects growing investor confidence in GeneDx's financial health and growth trajectory in the competitive genomics and diagnostics sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113281621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113281621","market":"nz","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings Soars 5.43% on Strong Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance significantly exceeded analyst expectations, particularly in terms of revenue and adjusted earnings per share.</p>\n\n<p>According to the financial report, GeneDx posted Q3 revenue of $116.7 million, substantially outperforming the IBES estimate of $104.1 million. This represents a 52% year-over-year growth. The company's adjusted earnings per share came in at $0.49, beating the consensus estimate of $0.39. Notably, exome and genome test revenue grew by 65% year-over-year, driven by a 33% increase in test volumes.</p>\n\n<p>In light of the strong performance, GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, up from the previous range of $400 million to $415 million. The company also expects 53% to 55% growth in exome and genome revenue for the full year. Additionally, GeneDx announced it had received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, underscoring its innovative leadership in the genomics space. The market's enthusiastic response to these results and outlook improvements reflects growing investor confidence in GeneDx's financial health and growth trajectory in the competitive genomics and diagnostics sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings Soars 5.43% on Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings Soars 5.43% on Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 01:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance significantly exceeded analyst expectations, particularly in terms of revenue and adjusted earnings per share.</p>\n\n<p>According to the financial report, GeneDx posted Q3 revenue of $116.7 million, substantially outperforming the IBES estimate of $104.1 million. This represents a 52% year-over-year growth. The company's adjusted earnings per share came in at $0.49, beating the consensus estimate of $0.39. Notably, exome and genome test revenue grew by 65% year-over-year, driven by a 33% increase in test volumes.</p>\n\n<p>In light of the strong performance, GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, up from the previous range of $400 million to $415 million. The company also expects 53% to 55% growth in exome and genome revenue for the full year. Additionally, GeneDx announced it had received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, underscoring its innovative leadership in the genomics space. The market's enthusiastic response to these results and outlook improvements reflects growing investor confidence in GeneDx's financial health and growth trajectory in the competitive genomics and diagnostics sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1113281621","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113281621","pubTimestamp":1761672398,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"个股赛道|GeneDx Holdings第三季度业绩强劲飙升5.43%并上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance significantly exceeded analyst expectations, particularly in terms of revenue and adjusted earnings per share.\nAccording to the financial report, GeneDx posted Q3 revenue of $116.7 million, substantially outperforming the IBES estimate of $104.1 million. This represents a 52% year-over-year growth. The company's adjusted earnings per share came in at $0.49, beating the consensus estimate of $0.39. Notably, exome and genome test revenue grew by 65% year-over-year, driven by a 33% increase in test volumes.\nIn light of the strong performance, GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, up from the previous range of $400 million to $415 million. The company also expects 53% to 55% growth in exome and genome revenue for the full year. Additionally, GeneDx announced it had received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, underscoring its innovative leadership in the genomics space. The market's enthusiastic response to these results and outlook improvements reflects growing investor confidence in GeneDx's financial health and growth trajectory in the competitive genomics and diagnostics sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113281621","isCrawlerRequest":true}